NO20071322L - Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof - Google Patents

Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof

Info

Publication number
NO20071322L
NO20071322L NO20071322A NO20071322A NO20071322L NO 20071322 L NO20071322 L NO 20071322L NO 20071322 A NO20071322 A NO 20071322A NO 20071322 A NO20071322 A NO 20071322A NO 20071322 L NO20071322 L NO 20071322L
Authority
NO
Norway
Prior art keywords
growth hormone
human growth
preparation
polyethylene glycol
branched polyethylene
Prior art date
Application number
NO20071322A
Other languages
Norwegian (no)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071322(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20071322L publication Critical patent/NO20071322L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en PEGylering av menneskelig veksthormon (hGH) ved bruk av et glycerolforgrenet PEG. Det beskrives videre prosesser for PEGylering av hGH. I tillegg beskriver oppfinnelsen farmasøytiske preparater omfattende PEGylert hGH. En ytterligere utførelsesform er bruken av PEGylert hGH for behandling av vekst- og utviklingsforstyrrelser.A PEGylation of human growth hormone (hGH) is described using a glycerol-branched PEG. Further processes for PEGylation of hGH are described. In addition, the invention discloses pharmaceutical compositions comprising PEGylated hGH. A further embodiment is the use of PEGylated hGH for the treatment of growth and development disorders.

NO20071322A 2004-08-31 2007-03-09 Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof NO20071322L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20071322L true NO20071322L (en) 2007-05-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071322A NO20071322L (en) 2004-08-31 2007-03-09 Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR9812267B1 (en) 1997-07-14 2013-11-26 Recombinant Growth Hormone.
EP1144613B2 (en) 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
MX2008014358A (en) * 2006-05-12 2008-11-24 Dong A Pharm Co Ltd Polyethylene glycol-interferon alpha conjugate.
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
WO2010011096A2 (en) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AU2009276458B2 (en) 2008-07-31 2014-06-19 Pharmaessentia Corp. Peptide-polymer conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
PT2355853T (en) * 2008-10-10 2017-03-15 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
SI2340271T1 (en) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Polymer-bioactive agent conjugates
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
WO2014110867A1 (en) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
SI3215193T1 (en) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dosage regimen for pegylated interferon
JP7227633B2 (en) * 2017-12-29 2023-02-22 エフ． ホフマン－ラ ロシュ エージー． Methods for providing PEGylated protein compositions
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
JP7137625B2 (en) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Methods for providing PEGylated protein compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
BR9812267B1 (en) * 1997-07-14 2013-11-26 Recombinant Growth Hormone.
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL162031A0 (en) * 2001-11-20 2005-11-20 Pharmacia Corp Chemically-modified human growth hormone conjugates
AP2005003246A0 (en) * 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
TR201907313T4 (en) * 2003-05-23 2019-06-21 Nektar Therapeutics PEG derivatives containing two PEG chains.

Also Published As

Publication number Publication date
ECSP077281A (en) 2007-03-29
MX2007002441A (en) 2007-05-04
IL181085A0 (en) 2007-07-04
EA200700380A1 (en) 2007-10-26
GT200500235A (en) 2006-03-21
ZA200701802B (en) 2008-08-27
NL1029828C2 (en) 2006-10-20
NL1029828A1 (en) 2006-03-01
WO2006024953A3 (en) 2007-01-18
JP2008511610A (en) 2008-04-17
CA2577999A1 (en) 2006-03-09
KR20070042567A (en) 2007-04-23
EP1789092A2 (en) 2007-05-30
PE20060654A1 (en) 2006-08-12
MA28908B1 (en) 2007-10-01
BRPI0515118A (en) 2008-07-01
CR8942A (en) 2007-08-16
AP2007003919A0 (en) 2007-02-28
AU2005278903A1 (en) 2006-03-09
TW200621291A (en) 2006-07-01
CN101010105A (en) 2007-08-01
WO2006024953A2 (en) 2006-03-09
AR050851A1 (en) 2006-11-29
UY29088A1 (en) 2006-03-31
TNSN07078A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
NO20071322L (en) Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
CY1119309T1 (en) COOPERATIVE USE OF TOY (+) - 1,4-Dihydro-7 - [(3S, 4S) -3-Methoxy-4- (Methylamino) -1-Pyrrolidinyl] -4-oxo-1 (2-thiazolyl) -1, 8-Naphthyridine-3-carboxylic acid and cytochrome c (ARA-C) for the treatment of leukemia
ATE463239T1 (en) METHOD FOR PRODUCING STERILE SUSPENSIONS OR LYOPHILISATES OF POORLY SOLUBLE BASIC PEPTIDE COMPLEXES, PHARMACEUTICAL FORMULATIONS CONTAINING THESE AND THEIR USE AS MEDICINAL PRODUCTS
NO20063926L (en) N-terminal monopegylated human growth hormone conjugates, methods of preparation and use thereof
WO2006004959A3 (en) Pegylated interferon alpha-1b
DK1079806T3 (en) Preparations for the application of anti-inflammatory, in particular antiseptic agents and / or agents promoting the healing of wounds, to the upper respiratory tract and / or the ear
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
RU2008145084A (en) ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
NO20060924L (en) Composition of a VEGF antagonist and an anti-proliferative agent
YU75903A (en) Thiohydantoins and use thereof for treating diabetes
CY1112257T1 (en) METHODS FOR TREATMENT OF INFLAMMATORY DISEASES USING SPECIAL BATTERIES OF HUMAN VASCULAR-2
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
DE60323090D1 (en) 1H-IMIDAZOÄ4,5-CÜCHINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
WO2008082507A3 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
DK1223990T3 (en) Formulations of hyaluronic acid for delivery of osteogenic proteins
DK1450771T3 (en) Pharmaceutical compositions for treating skin lesions and mucous membranes and methods and kits for their use
DK2229440T3 (en) RECOMBINANT ELASTASE PROTEINS AND PROCEDURES FOR PRODUCING AND USING THEREOF
DE50211137D1 (en) SIDE-CHAIN HALOGENATED AMINODICARBONE ACID DERIVATIVES AS A MEDICAMENT FOR TREATING HEART CIRCULAR DISEASES
NO20051261L (en) Morphine-6-glukuronidsalt
DK1189627T3 (en) Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
NO20024673L (en) Controlled-release pharmaceutical composition for oral use containing midodrine and / or desglymidodrine
DK1596879T3 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application